Why is Replimune stock volatile today?
Replimune Group shares rose in pre-market to about $12.87 after the FDA granted accelerated approval for Tudriqev with Bristol Myers Squibb’s nivolumab in unresectable advanced cutaneous melanoma after prior anti-PD-1 therapy. The FDA cited IGNYTE Phase 1/2 results: ORR 24.2% (91 patients) and median DoR 14.1 months. Analysts upgraded and set targets up to $17.00, while confirmatory data remains required.
How this was made
The 30-second read
Why it matters
The FDA’s accelerated approval for Tudriqev plus nivolumab is a fresh regulatory milestone that can re-rate the probability of commercialization, but it does not eliminate the need for confirmatory clinical benefit.
Market read
Regulatory approval plus analyst upgrades drove pre-market strength and a new 52-week high, but confirmatory-trial requirements keep volatility elevated.
What to watch
The article notes the single-arm IGNYTE evidence was previously deemed insufficient; confirmatory IGNYTE-3 timing and endpoint selection remain key overhangs.
Background
Replimune’s Tudriqev had been rejected twice by the FDA (July 2025 and April 2026) based on insufficient evidence from the single-arm IGNYTE study.
Ticker impact
Replimune shares are reacting to FDA accelerated approval for Tudriqev plus Bristol Myers Squibb’s nivolumab after prior rejections.
Likely supports elevated trading and volatility near-term; downside risk persists until confirmatory IGNYTE-3 data de-risks benefit.
The article cites a new FDA approval after two prior denials, plus analyst upgrades and a new 52-week high, while also emphasizing confirmatory data requirements under the accelerated pathway.
Market effects
Highlights competitive dynamics in post-PD-1 cutaneous melanoma, favoring more accessible regimens versus logistically complex cell therapies.
No specific regional transmission beyond broad US equity index strength.
US FDA decision can influence global melanoma treatment adoption and investor sentiment toward similar oncology platforms.
Counterpoint
Accelerated approvals can reverse if confirmatory trials fail, so the initial pop may fade without durable efficacy.
Key entities
- companyReplimune Group Inc
Subject of the article; received FDA accelerated approval for Tudriqev in combination with nivolumab.
- drugTudriqev
Replimune therapy granted accelerated approval with nivolumab for unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy.
- drugnivolumab
Bristol Myers Squibb’s PD-1 therapy used in the approved combination regimen.
- regulatorFDA
Granted accelerated approval late Thursday evening, reversing prior denials.
- clinical_trialIGNYTE-3
Ongoing Phase 3 confirmatory study referenced as the remaining key de-risking step.
